Navigation Links
Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
Date:3/7/2012

crine.niddk.nih.gov/pubs/cushings/Cushings_Syndrome_FS.pdf">http://endocrine.niddk.nih.gov/pubs/cushings/Cushings_Syndrome_FS.pdf.  Accessed December 2011.
3.     Boscaro, M. Treatment of Pituitary-Dependent Cushing's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial. J Clin Endocrin Metabol. 2009;94(1):115-122.
4.     Newell-Price, J. The Diagnosis and Differential Diagnosis of Cushing's Syndrome and Pseudo-Cushing's States. Endocrine Reviews. 1998;19(5): 647-672.
5.     Pedroncelli, A. Medical Treatment of Cushing's Disease: Somatostatin Analogues and Pasireotide. Neuroendocrinology. 2010;92(suppl1):120-124.
6.     Lindholm, J. Incidence and Late Prognosis of Cushing's Syndrome: A Population-Based Study. The Journal of Clinical Endocrinology & Metabolism. 2001; 86(1):117-121.

Novartis Media Relations

Julie Masow

Novartis Corporation

+1 212 830 2465 (direct)

+1 862 579 8456 (mobile)

julie.masow@novartis.com

 

e-mail: us.mediarelations@novartis.com

Nicole Riley

Novartis Oncology

+1 862 778 3110 (direct)

+1 862 926 9040 (mobile)

nicole.riley@novartis.com

 

 

For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis.
For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 5 Virtual Health Technologies, Inc. (OTC Bulletin Board: VHGI) ... Intent to sell all health care related assets to Wound ... be paid $1,000,000 in cash and debt, 4,000,000 shares of ... VHGI. WNDM closed at $2.00 per share on 11/4/09 ...
... FRANCISCO, Calif., Nov. 5 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration has granted voreloxin orphan drug designation ... is currently conducting two Phase 2 clinical trials of ... of voreloxin in newly diagnosed elderly AML patients unlikely ...
Cached Medicine Technology:OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 2OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 3Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Health and the University of Colorado Denver have discovered a ... acute lung injury. Acute lung injury (ALI) is often caused ... in the blood, and fluid in the lungs. It is ... afflicting almost 200,000 people in the United States each year, ...
... Pharos Innovations, a pioneer in,assisting clients to ... a device-free remote monitoring platform,today announced it is ... of two key appointments in medical informatics and ... http://www.newscom.com/cgi-bin/prnh/20080306/AQTH086LOGO ) , ...
... N.Y., Jan. 16 Bausch & Lomb, the ... Valenti, III, will join Bausch & Lomb as ... month."Pete possesses deep leadership experience, as well as ... Stuart Heap, corporate vice president and global president, ...
... 16 /PRNewswire-FirstCall/ - Thomas E. Gardner, Chairman, announced ... appointed to the NUCRYST Pharmaceuticals, Board of Directors. ... Executive Officer of The Westaim Corporation ("Westaim"), NUCRYST,s ... common shares. Prior to his appointment as President ...
... 16 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... of medical devices worldwide, today announced updates on ... and international markets in,2009. , ... of ten products, achieving the goals,for new product ...
... in Guangdong ProvincePROVO, Utah, Jan. 15 Nu Skin ... that it has received official notification from the Chinese ... selling activities in four cities in the Guangdong province ... Skin Enterprises the opportunity to offer a direct selling ...
Cached Medicine News:Health News:Gene associated with reduced mortality from acute lung injury 2Health News:Pharos Innovations Strengthens Leadership Team, Informatics Program 2Health News:Pharos Innovations Strengthens Leadership Team, Informatics Program 3Health News:Bausch & Lomb Names Peter Valenti, III, as President, North America, Vision Care 2Health News:NUCRYST Pharmaceuticals appoints a new director 2Health News:NUCRYST Pharmaceuticals appoints a new director 3Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 2Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 3Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 4Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 5Health News:Nu Skin Enterprises Receives Broader Direct Selling Authorization in China 2
... firm support and stabilization for non-operable hip ... total hip arthroplasty. Neoprene padding is secured ... wicking interface. This brace may be ordered ... Genesis joints. , ,POSTERIOR PANEL: ...
... Philippon Post-Op Hip Brace was developed in ... of Sports Medicine/Hip Disorders at the University ... as well as abduction and adduction in ... brace can also lock in any position ...
... The B3 Triplanar hip ... planes; Flexion - extension, abduction ... standard on our Boston Post-Op ... on our custom Hip Spicas ...
... Abduction and rotation for ... and fractures. Preset at ... adjustable flexion and extension ... back panel. Available in ...
Medicine Products: